Dario M. Ferri

Dario M. Ferri

Auto-generated profile, based on publicly available information

Dario M. Ferri

Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in JAMA
Verified
Journal Article
Open access
PDF file
DRDaniel Rayner
Daniel Rayner
DFDario M. Ferri
Dario M. Ferri
GGGordon H. Guyatt
Gordon H. Guyatt
POPaul M. O’byrne
Paul M. O’byrne
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
DCDerek K. Chu
Derek K. Chu
Asthma has a global prevalence of 262 million people and is characterized by airway inflammation and variable airflow obstruction.1 Reliever inhalers, including bronchodilator-only relievers (short-acting β agonists [SABA]), such as albuterol, or inhaled corticosteroids (ICS) with either SABA or formoterol, are indicated for patients with asthma to acutely relieve symptoms of dyspnea, wheezing, or cough.1 Although the Global Initiative for Asthma (GINA)1 and the National Asthma Education and Prevention Program2 recommend ICS-formoterol as the preferred reliever over SABA alone, the US Food and Drug Administration (FDA) recently approved ICS-SABA as a reliever inhaler; the optimal asthma reliever remains unclear.3 Furthermore, guideline recommendations do not sufficiently differentiate between ICS-SABA and SABA-alone relievers, and the relative benefits of ICS-formoterol compared with ICS-SABA on clinical outcomes remain unclear.1,2 This systematic review evaluated inhaled relievers for improving outcomes in asthma.

15 September 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JJJenny Jongstra-Bilen
Jenny Jongstra-Bilen
CZCindy X. Zhang
Cindy X. Zhang
TWTimothy Wisnicki
Timothy Wisnicki
MLMengyi K. Li
Mengyi K. Li
SWSamantha White-Alfred
Samantha White-Alfred
MCMyron I Cybulsky
Myron I Cybulsky
Hypercholesterolemia is a key risk factor for atherosclerosis and leads to the uptake of native and oxidized low-density lipoprotein (oxLDL) by macrophages (Mϕs) and foam cell formation. Inflammatory processes accompany Mϕ foam cell formation in the artery wall, yet the relationship between Mϕ lipid loading and their response to inflammatory stimuli remains elusive. We investigated proinflammatory gene expression in thioglycollate-elicited peritoneal Mϕs, bone marrow–derived Mϕs and dendritic cells, and RAW264.7 cells. Loading with oxLDL did not induce peritoneal Mϕ apoptosis or modulate basal-level expression of proinflammatory genes. Upon stimulation of TLR4, the rapid induction of IFN-β was inhibited in cells loaded with oxLDL, whereas the induction of other proinflammatory genes by TLR4 (LPS), TLR3 (polyriboinosinic-polyribocytidylic acid), TLR2 (Pam3CSK4), and TLR9 (CpG) remained comparable within the first 2 h. Subsequently, the expression of a subset of proinflammatory genes (e.g., IL-1β, IL-6, CCL5) was reduced in oxLDL-loaded cells at the level of transcription. This phenomenon was partially dependent on NF erythroid 2–related factor 2 (NRF2) but not on nuclear liver X receptors α and β (LXRα,β), peroxisome proliferator-activated receptor-γ (PPARγ), and activating transcription factor 3 (ATF3). LPS-induced NF-κB reporter activity and intracellular signaling by NF-κB and MAPK pathways were comparable in oxLDL-loaded Mϕs, yet the binding of p65/RelA (the prototypic NF-κB family member) was reduced at IL-6 and CCL5 promoters. This study revealed that oxLDL loading of Mϕs negatively regulates transcription at late stages of TLR-induced proinflammatory gene expression and implicates epigenetic mechanisms such as histone deacetylase activity.

29 November 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YBYuriy Baglaenko
Yuriy Baglaenko
NCNan-Hua Chang
Nan-Hua Chang
SJSindhu Johnson
Sindhu Johnson
WHWaleed Hafiz
Waleed Hafiz
KMKieran Manion
Kieran Manion
JWJoan Wither
Joan Wither
Diagnosis of systemic autoimmune rheumatic diseases (SARD) relies on the presence of hallmark anti-nuclear antibodies (ANA), many of which can be detected years before clinical manifestations. However, ANAs are also seen in healthy individuals, most of whom will not develop SARD. Here, we examined a unique cohort of asymptomatic ANA+ individuals to determine whether they share any of the cellular immunologic features seen in SARD. Healthy ANA− controls and ANA+ (ANA ≥1:160 by immunofluorescence) participants with no SARD criteria, with at least one criterion (undifferentiated connective tissue disease (UCTD)), or meeting SARD classification criteria were recruited. Peripheral blood cellular immunological changes were assessed by flow cytometry and transcript levels of BAFF, interferon (IFN)-induced and plasma cell-expressed genes were quantified by NanoString. A number of the immunologic abnormalities seen in SARD, including changes in peripheral B (switched memory) and T (iNKT, T regulatory, activated memory T follicular helper) subsets and B cell activation, were also seen in asymptomatic ANA+ subjects and those with UCTD. The extent of these immunologic changes correlated with ANA titer or the number of different specific ANAs produced. Principal component analysis of the cellular data indicated that a significant proportion of asymptomatic ANA+ subjects and subjects with UCTD clustered with patients with early SARD, rather than ANA− healthy controls. ANA production is associated with altered T and B cell activation even in asymptomatic individuals. Some of the currently accepted cellular features of SARD may be associated with ANA production rather than the immunologic events that cause symptoms in SARD.

28 February 2023 in University of Toronto Medical Journal
Verified
Journal Article
Open access
PDF file
DFDario Ferri
Dario Ferri
CMClara Moore
Clara Moore
KMKyung Joon Mun
Kyung Joon Mun
ACAnna Chen
Anna Chen
DKDebra Katzman
Debra Katzman
JNJoyce Nyhof-Young
Joyce Nyhof-Young
Background: Evidence-based medicine (EBM) allows physicians to integrate evidence, clinical experience, and patient values into clinical decision making and thus has been readily incorporated into medical education; however, there is limited research capturing the perceptions of both student and educator in their experiences in engaging with an EBM-based research curriculum. Assessing the perceptions of both these key stakeholders represents an important area of research as it can help to inform EBM curriculum integration and evaluation efforts. Methods: This qualitative study utilizes a constructivist framework to assess the thoughts, beliefs, and feelings of students and tutors interacting with a 2-year EBM-based research curriculum. Students completed semi-structured interviews and tutors completed online surveys to explore their perceptions and experiences. Interview transcripts and survey responses were analysed using conventional descriptive content analysis to create a set of recommendations for EBM curriculum development. Results: 13 students and 20 tutors participated, and four major themes were identified. Students noted EBM education was most effective when opportunities existed to apply research skills, complete practical research experience, engage actively in learning, and integrate clinical and research concepts. Tutors found the curriculum to be effective but noted it was challenging to accommodate for the diversity of student knowledge and interest in research. Conclusion: This study provides a general set of recommendations for the design, implementation, and refinement of EBM-based research curricula to facilitate student learning through focusing on 1) research consumption, 2) emphasizing application, 3) emphasizing interactivity, 4) curriculum integration, and 5) catering towards student heterogeneity.